| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 848.90 | 4.7% | 2.8% |
| Total Income | 848.90 | 4.7% | 2.8% |
| Expenditure | 746.80 | 0.2% | 4.5% |
| PBT | — | ||
| Net Profit | -15.00 | 58.2% | 500.0% |
| OPM | 12.03% | 3.91pp | 1.49pp |
| NPM | -1.77% | 2.66pp | 1.46pp |
| EPS | -0.12 | 57.1% | 500.0% |
Surgery Partners Announces Q2 2026 Results and Reaffirms Full Year Guidance
10 Aug 2026 · 10 Aug, 5:07 pm
Summary
Surgery Partners announced its second quarter 2026 results, with revenue increasing 2.7% year-over-year to $848.9 million, and same-facility revenues growing 5.0%. The company reported a net loss of $15.0 million for the quarter, with Adjusted EBITDA at $125.2 million. Management reaffirmed the full-year 2026 guidance for revenue between $3.35 billion and $3.45 billion and Adjusted EBITDA of at least $530 million, highlighting disciplined execution and strategic portfolio optimization.
Key Highlights
- 1
Surgery Partners reported second quarter 2026 revenues increased by 2.7% to $848.9 million compared to $826.2 million in the prior year period.
- 2
Same-facility revenues for the second quarter of 2026 increased by 5.0% year-over-year, driven by a 4.8% increase in revenue per case.
- 3
The Company reported a net loss attributable to Surgery Partners, Inc. of $15.0 million for the second quarter of 2026.
- 4
Adjusted EBITDA for the second quarter of 2026 was $125.2 million, compared to $129.0 million in the same period of 2025.
- 5
Year-to-date 2026 revenues increased 3.6% to $1,659.8 million compared to $1,602.2 million for the 2025 period.
- 6
The Company reaffirmed its full year 2026 revenue guidance to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding a pending divestiture.
- 7
Same-facility cases increased by 0.3% for the second quarter of 2026.
Management Comments
Eric Evans
We are pleased with our progress this quarter, which reflects disciplined execution against our key strategic priorities to support a return to growth and reinforces our conviction in our short stay surgical platform. The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy, as we take decisive actions to improve our financial profile and sharpen our strategic focus. Looking ahead, we will capitalize on the structural tailwinds underpinning long-term ASC market growth, enhance operational efficiency, and thoughtfully deploy capital to deliver long-term value for our shareholders.
David T. Doherty
Our financial results in the second quarter demonstrate the momentum of our ongoing initiatives to improve performance, and we are reiterating full-year guidance as a result. The Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals, will further strengthen our financial position, through improved cash conversion and deleveraging. Going forward, we are committed to disciplined capital allocation to support the continued growth of our business.
Informational and educational content only. Not investment advice.